LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1060 participants.
Also called NCT02077257
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,060 participants
- Sponsor
- Registry
-
NCT02077257
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02077257. Randomized; no masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Rosuvastatin
- Lead sponsor
- Committee of Cardio-Cerebral-Vascular Diseases of GSC
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct02077257- Content hash
b3b547232b5051bd21c432bd0fc146b602fa612c0ec0f76190b4a6fc44337b53